EP1112494A1 - Method for the rapid screening of analytes - Google Patents
Method for the rapid screening of analytesInfo
- Publication number
- EP1112494A1 EP1112494A1 EP98940489A EP98940489A EP1112494A1 EP 1112494 A1 EP1112494 A1 EP 1112494A1 EP 98940489 A EP98940489 A EP 98940489A EP 98940489 A EP98940489 A EP 98940489A EP 1112494 A1 EP1112494 A1 EP 1112494A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- solid support
- analytes
- analyte
- solid
- semi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 238000012216 screening Methods 0.000 title claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 120
- 239000012491 analyte Substances 0.000 claims abstract description 34
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 230000003993 interaction Effects 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229920001817 Agar Polymers 0.000 claims description 12
- 239000008272 agar Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- 239000011324 bead Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000002356 single layer Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- 108020003215 DNA Probes Proteins 0.000 claims description 2
- 239000003298 DNA probe Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000003049 inorganic solvent Substances 0.000 claims description 2
- 229910001867 inorganic solvent Inorganic materials 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 238000013207 serial dilution Methods 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 229940000406 drug candidate Drugs 0.000 abstract description 4
- 231100000673 dose–response relationship Toxicity 0.000 abstract description 3
- 239000007790 solid phase Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 18
- 238000009792 diffusion process Methods 0.000 description 17
- 244000005700 microbiome Species 0.000 description 14
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 229960002378 oftasceine Drugs 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012894 fetal calf serum Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000013537 high throughput screening Methods 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 7
- 239000012979 RPMI medium Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 7
- 238000011049 filling Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229950006243 loviride Drugs 0.000 description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- -1 1 % Pen-Strep Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241001076939 Artines Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00511—Walls of reactor vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00513—Essentially linear supports
- B01J2219/00518—Essentially linear supports in the shape of tapes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00513—Essentially linear supports
- B01J2219/0052—Essentially linear supports in the shape of elongated tubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00531—Sheets essentially square
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00533—Sheets essentially rectangular
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00536—Sheets in the shape of disks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/0061—The surface being organic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00614—Delimitation of the attachment areas
- B01J2219/00621—Delimitation of the attachment areas by physical means, e.g. trenches, raised areas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00702—Processes involving means for analysing and characterising the products
- B01J2219/00707—Processes involving means for analysing and characterising the products separated from the reactor apparatus
Definitions
- This invention relates to a method for the rapid screening of large numbers of analytes, including the rapid screening of chemical compounds in liquid form for use as potential drugs.
- HTS high throughput screening
- the microtitre plate plays a central role being the standard device in which assays are performed.
- the microtitre plate has determined the design of liquid handling equipment such as programmable liquid handling work stations and has also led to the development of microtitre plate peripherals for filtration, washing, reading and other operations involved in HTS.
- microtitre plate-based equipment has been integrated with robotic manipulators.
- the central role of the microtitre plate and the continuously increasing throughput requirements has led to ever larger and more complex HTS-modules.
- complex modules include robot rails to access wider surfaces, automatic and larger microtitre plate incubators and storage devices for disposables. Additionally, complex operations scheduling programmes and integration software are required for optimal management of all of the hardware components.
- the central role of the microtitre plate also determines other aspects of a typical screening process such as the chemical library aspects.
- compounds are synthesised, stored and catalogued at central chemical repositories from which new compounds are dispatched upon request from biological assay laboratories in- or outside an organisation. Often, each new compound has to be weighed and dissolved prior to each new assay. Therefore, it is essential that the compounds can be individually accessed and routinely retrieved.
- HTS-system layouts and capacities efforts are being made to adapt the physical storage conditions of compounds to the microtitre plate format.
- dimethylsulfoxide-( DMSO ) dissolved stock compound stock solutions which are stored in microtitre plate format and whereby each compound is addressable through its location.
- HTS-infrastructure The basis of the HTS-infrastructure is still the 96-well standard microtitre plate and the majority of screening systems developed to date have been developed for use with this format.
- microtitre plates e.g. 384-, 864-, 1536 and 9600 well plates
- screening formats are likely to change considerably in the future, screening systems must have sufficient flexibility to meet this challenge.
- the invention provides a method for the rapid screening of analytes, comprising the steps of:
- the method according to the invention allows for the manipulation of thousands of different analytes simultaneously.
- step a) of the method according to the invention comprises (i) disposing the analytes within individually identifiable containers, and (ii) transferring the analytes from the containers to the solid support(s) in such a manner as to maintain the transferred contents of each container separate from those of each other container.
- the individually identifiable containers are preferably selected from tubes, including capillary tubes, pens, including plotter pens, and print heads or any container allowing for the storage and direct application of an analyte from the container to a given solid support.
- the individually identifiable containers are an array of capillary tubes each of which is identifiable according to its position within the array, and wherein transfer of the analytes to the solid support(s) occurs by dispensing thereof through the open ends of the capillary tubes.
- Especially preferred arrays are individual containers disposed in concentric or spiral arrays.
- Transfer of the analytes to the solid support can be achieved by dispensing said analytes from the open ends of the capilliary tubes to the solid support with or without direct contact between the capilliary tubes and the solid support.
- the analytes can be transferred to the solid support in variable amounts. Thus, by varying the drop size transferred one can achieve a serial dilution, if required.
- Simultaneous transfer of analyte from the capilliaries can be achieved by applying a stimulus such as a change of pressure using a piezoelectric element.
- a stimulus such as a change of pressure
- a piezoelectric element Alternatively, one can use high frequency conditions to break a liquid column into droplets which are dispensed to the solid support, as required.
- the droplet size will typically be nanolitre or picolitre in volume.
- an assay format in accordance with the invention where the analyte is not pipetted in as is currently the norm but is applied directly from its individual container to the assay medium.
- the individually identifiable containers described herein provide a means of storing stock compounds which can be accessed and used as required.
- the analyte application units can consist of individual identifiable containers assembled in addressable compartments that can be retrieved automatically as a whole and from which the analytes can be applied directly to a solid support.
- a preferred embodiment of the identifiable container is a capilliary tube and stock compounds in solution are taken up in a plurality of such capilliary tubes by capilliary action.
- stock compounds in solution are taken up in a plurality of such capilliary tubes by capilliary action.
- capillaries can be filled without special energy requirements.
- Capillary tubes filled with stock solutions of compounds can be stored at desired temperatures and conditions.
- the method according to the invention allows for the simultaneous mass application of analytes onto a solid support.
- analyte containers can also suitably be individual addressable plotter pen-like devices allowing simultaneous drawing of parallel lines of analyte on a solid support of choice.
- the compounds which can be disposed as a pattern of discrete spots or lines, are left to dry on the solid phase.
- the solid support is of a substantially flat, disc-, rectangular- or square- shape.
- the solid support can comprise a material which allows for spontaneous release of the analyte(s) when applied thereto.
- the solid support can comprise a material which allows for controlled release of the analyte(s) when applied thereto.
- the material can be said semi-solid medium.
- each analyte when applied to the solid support it diffuses thereon so as to produce a concentration gradient.
- the surface of the solid support onto which the analytes are applied is selected from polymers, ceramics, metals, cellulose and glass.
- said semi-solid medium is disposed on a carrier.
- the solid support is in the form of a flexible film or tape onto which the target-containing semi-solid medium is applied, whereby the method can be automated using a system of rollers to progress the flexible film or tape through the various steps of the method.
- the carrier can be covered by a further layer of film or tape and is thereby sandwiched between the solid support and the covering layer.
- the solid support or covering layer (if present) can be provided with a track for the recordal of information regarding the applied analytes, whereby the information can be read and processed simultaneously with the measurement of analyte-target interactions in an automated process.
- the solid support is itself a detector or forms part of a detector.
- the solid support is preferably selected from a SiO : wafer, a charge-coupled device and a photographic film.
- the surface of the solid support can be coated with a membrane, a molecular monolayer, a cellular monolayer or a Langmuir-Blodgett film.
- the solid support is itself an information carrier which carries information in electronic, magnetic or digitised form.
- the surface of the solid support is reflective.
- the surface can be the reflective surface of a compact disc.
- the method according to the invention can further comprise the step of copying said compact disc to a writable compact disc.
- the semi-solid medium comprises a substance which provides a semi-solid or viscous liquid environment allowing controlled release of said anlaytes to said target.
- the substance which provides a semi-solid or viscous liquid environment is selected from gelatin, polysaccharides such as agar and agarose, and polymers such as methylcellulose and polyacrylamide or a so-called intelligent material.
- Such substances can also be used to control the release of the analytes when applied thereto.
- So-called intelligent materials are natural and synthetic polymer gels that are undergo phase transitions and critical phenomena, for example phase transitions accompanied by a reversible, discontinuous volume change as large as several hundred times, in response to infinitesimal changes in environmental conditions.
- Examples of so-called intelligent materials are polymeric gel- type materials, more particularly hydrogels that can take up a fluid and subsequently release that fluid in response to a chemical or physical stimulus or trigger.
- An example of a chemical stimulus is a change of pH or ionic or solvent composition and an example of a physical stimulus is light of a particular wave-length or a laser beam, a change of temperature or a small electric field.
- a gel containing N-isopropylacrylamide (main constituent) and the light-sensitive chromophore, the trisodium salt of copper undergoes phase transitions induced by visible light (Suzuki, A. and Tanaka, T (Nature ( 1990); 346, 345-347).
- thermo-sensitive polymers A range of suitable thermo-sensitive polymers is described by
- steps a) and b) are carried out simultaneously.
- each analyte is applied to a single solid support.
- the solid support is preferably of a rod shape or a spherical shape.
- each analyte-bearing solid support is contacted in step b) with a target in a separate compartment of a multi- compartmented apparatus, more especially said compartments are an arrangement of mini-wells in said apparatus.
- the analyte containers are small inert solid supports onto the surfaces of which analytes have been applied. Dipping of the solid supports into a liquid phase or semi-solid phase results in time-dependent release of analyte from the solid support into the liquid or semi-solid phase. In this way, dilutions of minute amounts of analytes in liquid or semi-solid phase can be obtained without the use of liquid handling devices.
- the final concentration of analyte released into the liquid or semi-solid phase is determined by the contact time between the analyte-carrying solid suppport and the liquid- or semi-solid phase.
- the analytes for rapid screening in the method according to the invention are preferably selected from chemical compounds, antigens, antibodies, DNA-probes, cells and beads and liposomes carrying an analyte of interest.
- the analytes when applied to the solid support, are dissolved in an organic or inorganic solvent.
- the solvent includes a so-called intelligent material responsive to a chemical or physical parameter such that each analyte, following application to the solid support and drying, liquifies in response to said chemical or physical parameter.
- the analyte in a preferred embodiment is a chemical compound for screening as a potential drug candidate.
- the targets are selected from prokaryotic cells, eukaryotic cells, viruses, molecules, receptors, beads, and combinations thereof.
- compound(s) means any synthetic, semi-synthetic or naturally-occuring compound or combination thereof.
- the targets are cells equipped with reporter functions.
- the targets are mammalian cells equipped with single or multiple reporter construct(s).
- the activity and/or expression of the reporter genes is dependent on the impact of the specific experimental conditions, for example the in vitro effect of compounds released from the solid support to a semi-solid phase.
- the incubation unit used in this embodiment will typically be an incubator of the type that is generally used for tissue culture.
- the detection unit used to measure the compound-cell interaction will suitably consist of an inverted microscope (e.g. Zeiss Axiovert 100) coupled to a video camera (e.g. dage-MTI CCD72E) and computer system (e.g. PC 300 Mhz Pentium) with KS400 basic software and the graphic KS400 option.
- the inverted microscope can be further equipped with a scanning stage modified to fit all culture plate configurations ( from 6-well up to 9600 well formats ) as well as other formats of the type described herein and equipped with a stepper motor with a resolution of 17,600 steps per revolution.
- the KS400 software package provides easy to use menus for entering configuration, calibration and assay parameters or data analysis specifications.
- Other detection means include the use of computer-assisted image analysers.
- adherent cells are used as a target, these cells are grown confluently either covering the surface of the solid support or the surface of small beads which are then homogeneously suspended in the semi-solid phase.
- said analyte-target interactions are measured using one or more of the following methods: microscopic, colorimetric, fluorometric, luminometric, densitometric, isotopic, and physical measurements.
- the microscope can be configured for epifluorescence fitted with a stepper motor and a camera system. Image acquisition and interpretation can be PC controlled. It will be appreciated that the method according to the invention provides for the coupling of the principle of compound diffusion in semi-solid media containing experimental biological systems to image microscopy systems. The invention also provides for visualising and determining the effect of compounds on prokaryotic and eukaryotic cell function.
- This visualisation can be achieved with genetically engineered cells embedded in a semi-solid medium and expressing single or multiple reporter genes of which the expression product(s) is/are an intracellular fluorophore(s) of specific excitation and emission wavelengths matching wavelength characteristics of a high density fluorescence image microscopy system.
- the method according to the invention typically comprises the steps of:
- suitable targets for use in accordance with the invention are genetically engineered green fluorescent protein (GFP)-express ⁇ ng MT4 cells containing the long term no repeat (LTR) promotor (pLTR-EGFP-C l ) and deposited at the BCCM on August 20, 1998, under Accession No. LMBP3879.
- pLTR-EGFP-C l (4777bp) is based on pEGFP-C l (Clontech).
- EGFP-Cl expression of the enchanced green fluorescent protein (EGFP) is controlled by the strong human cytomegalovirus immediate early promotor (589bp).
- EGFP-Cl expression of the enchanced green fluorescent protein (EGFP) is controlled by the strong human cytomegalovirus immediate early promotor (589bp).
- pLTR-EGFP-Cl the CMV promotor is replaced by the HIV- 1 long terminal repeat LTR (652bp) containing the highly inducible promotor in the U 3 region.
- Such cells when infected with HIV become fluorescent due to activation of LTR and expression of GFP. If a candidate drug inhibits HIV, for example by inhibiting the viral reverse transcriptase, protease or integrase fluorescence is reduced or totally inhibited and one observes progressively darkened regions in the area of the compound-target interaction.
- Step b) of the method according to the invention will typically involve maintaining the analytes and the targets under appropriate assay conditions and for a sufficient period of time for the release of the analytes from the solid support and the diffusion of said analytes into the liquid or semi-solid phase containing the targets of interest.
- Maintaining appropriate assay conditions will include maintaining correct temperature, osmolality, pH, tonicity and the like. These conditions are further determined by the nature of the targets.
- the temperature can range from about 4°C to about 50°C and pH can range from about 6.5 to about 7.5.
- Osmolality and tonicity will be chosen in a manner so that optimal cell-analyte interactions can be obtained.
- the only limitation on physical conditions is that the conditions used do not adversely affect cell viability nor interfere with analyte target interactions.
- the method according to the invention facilitates the use of a data management unit.
- a data management unit suitable comprises chemical compound library data with compound identification, history tracking and software technology allowing accessing and identification of compounds within the warehouse installation at all times.
- analyte application, analyte target interaction, incubation, detection and data interpretation are linked in such a way that the entire screening method according to the invention is a fully automated method from start to finish.
- One typical example of an automated method of rapid screening of compounds according to the invention comprises the steps of:
- Outer surfaces can contain digital information regarding the identity of the applied compounds which is read simultaneously during sample analysis as described in step 8. In this way, biological information and compound information can be read and processed at the same time.
- Fig. 1 illustrates the principle of compound diffusion in a semi- solid matrix as described in Example 1 at a cell density of 10E5/ml;
- Fig. 2 illustrates the principle of compound diffusion in a semi- solid matrix as described in Example 1 at a cell density of 10E6/ml;
- Fig. 3 illustrates the principle of compound diffusion in a semi- solid matrix as described in Example 1 at a cell density of 10E7/ml;
- Fig. 4 is a capillary tube holder device (8 x 12) as described in Example 2;
- Fig. 5 shows the fluorescence observed with GFP (green fluorescent protein) expressing MT4-cells (LTR (long term no repeat) promotor) in RPMI (Rosemount Park Memorial Institute) medium without phenol red, 10% FCS (fetal calf serum) and 1 % Pen-Strep (penicillin-streptomycin) in the absence (a) and in the presence of HIV- 1 (b) as described in Example 3;
- GFP green fluorescent protein
- LTR long term no repeat
- FCS fetal calf serum
- Pen-Strep penicillin-streptomycin
- Figs. 6(a) and (b) show the fluorescence observed with GFP expressing MT4-cells (LTR promotor) in semi-solid phase (RPMI medium without phenol red, 10% FCS, 1 % Pen-Strep, agar 0.34 %) in the absence (a) and in the presence of HIV- 1 (b) as described in Example 3;
- Figs. 7(a) - (e ) show the fluorescence observed with GFP- expressing MT4-cells ( LTR promotor) in RPMI medium (without phenol red and supplemented with 10% FCS, 1 % Pen-Strep) in the absence (a) and in the presence of HIV- 1 (b) and in the presence of HIV- 1 and the reverse transcriptase inhibitors: AZT (c), 3TC (d) and Loviride (e) at a final concentration of 2.5 ⁇ M in a total volume of 20 ⁇ l as described in Example 3;
- Figs. 8(a) - (e) show the fluorescence observed with GFP- expressing MT4-cells (LTR promotor) in semi-solid phase 0.34% agar in RPMI medium (RPMI medium without phenol red, supplemented with 10% FCS and 1% Pen-Strep) in the absence (a) and in the presence of HIV- 1 (b) and in the presence of HIV-1 and the reverse transcriptase inhibitors: AZT (c), 3TC (d) and Loviride (e) spotted ( 1 ⁇ l of a stock solution) onto a surface of a solid support at a concentration producing a 2.5 ⁇ M end concentration, assuming complete diffusion of the compounds in 20 ⁇ l semi-solid phase as described in Example 3;
- Fig. 9 shows the fluorescence observed with HIV-1 infected
- MT4-cells in semi-solid phase 0.34% agar in RPMI medium without phenol red, supplemented with 10% FCS and 1% Pen-Strep
- a solid support onto which l ⁇ l of 2.5 ⁇ M, 250 nM and 2.5 nM of reverse transcriptase inhibitors were applied, left to dry and kept for one week at 4°C prior to use as described in Example 3;
- Fig. 10 shows the fluorescence observed with HIV- 1 infected MT4-cells in medium (RPMI without phenol red, supplemented with 10% FCS and 1 % Pen-Strep) when HIV- 1 infected cells were added in medium to the wells of a 384-well tissue culture plate containing 1 ⁇ l of 2.5 ⁇ M, 250 nM and 2.5 nM of the reverse transcriptase inhibitors AZT, 3TC and Loviride. respectively as described in Example 3;
- Fig. 1 1 is a schematic representation of a solid support carrying spotted compounds in the method according to the invention
- Fig. 12 illustrates schematically how the distance between capillaries in an array can be varied and adapted to the specific requirements of the method according to the invention
- Fig. 13 is a diffusion pattern of calcein in a semi-solid phase on a solid support in accordance with the invention.
- Fig. 14 illustrates the principle of automated on-line mega- throughput screening using the method according to the invention
- Fig. 15 is a schematic representation with exploded detail of capilliary tube sorting means
- Figs. 16(a) - (c) show the movement of the capilliary tubes of
- Fig. 17 illustrates the filling of the capilliary tubes of Fig. 15;
- Fig. 18 shows a screw device used to reduce the spacing between the capilliary tubes of Fig. 15;
- Fig. 19 shows the individual capilliary tubes of Fig. 15 being formed into a spiral array
- Fig. 20 illustrates means by which the liquid in the capilliary tubes of Fig. 15 is released onto a solid support
- Fig. 21 illustrates a sample deposition pattern
- Fig. 22 is a plan view of a solid support with analytes spotted thereon.
- Fig. 23 illustrates the application of a semi-solid phase to the solid support.
- a cell viability marker was dissolved at a concentration of 5 mM in dimethyl sulfoxide (DMSO).
- DMSO dimethyl sulfoxide
- a glass capillary tube with a total volume capacity of 0.5 ⁇ l was dipped into the calcein solution and filled by capillary action.
- the tip of the capillary tube was then contacted with a polystyrene surface in a such a way that a small drop of calcein solution was delivered from the capillary tube to the plastic surface.
- a bundle of capillaries filled with calcein and arranged (8 x 12) in a holder device as depicted in Fig. 4 was contacted with a surface of polystyrene so that a drop of calcein was delivered simultaneously from each capillary to the polystyrene surface.
- the holder device is indicated generally at 10 and comprises capillary tubes 1 1 mounted in plates 12, 13 for maintaining the capillary tubes 1 1 in the desired relationship with respect to each other.
- a homogeneous suspension of MT4 cells in RPMI 1640 medium supplemented with 10% FCS, 1% Pen-Strep and 0.34% agar was layered over the spots. After an incubation period of 2 hours (humidified atmosphere, 5% carbon dioxide) it was found that for each of the spots the distance of diffusion of the calcein in the semi-solid matrix was reflected by the fluorescence of the embedded MT4 cells.
- Compound target interaction Effect of anti-HIV compounds on the fluorescence of GFP-expressing MT4 cells (LTR promotor) in the presence of HIV-1 in a semi-solid phase
- MT4 cells were collected from tissue culture flasks and suspended at 10E7/ml in RPMI medium. This cell suspension was further equally divided into four tubes. These tubes were then centrifuged at 450 g, for 10 min. To the cell pellets obtained after centrifugation of two of these tubes. 200 ⁇ l HIV suspension in RPMI medium were added for a period of 2 hours at 37°C. The other two tubes were treated in the same way, except that no virus was added. After an incubation time of 2 hours, agar solution (39°C) was added to one tube containing cells and HIV and to one tube only containing cells at a final concentration of 0.34%. Then, 20 ⁇ l of the cell suspension in agar and 20 ⁇ l of the cell/virus-agar suspension were added to the different wells of a 384-well plate containing the spotted compounds as set forth above.
- results obtained show that the concentration-dependent effects of RT inhibitors on HIV-1 infection as reflected by GFP-expressing MT4-cells are observed in semi-solid phase and that the nature of the compound and its effectiveness for HIV- 1 RT inhibition is not affected by the use of a semi-solid medium.
- a solid support 20 carrying compounds 21 which have been spotted thereon from an array of 196 bundles of capillary tubess (not shown) each carrying 110 capillary tubes so that 21,560 compounds are spotted onto the solid support 20.
- Fig. 12 illustrates how the distance between the capillaries in an array can be varied ( 1.414 mm, 1 mm, 2.236 mm, 2 mm, 3.623 mm, 3 mm) to meet the specific requirements of a screening method in accordance with the invention.
- Fig. 13 is a diffusion pattern of calcein in a semi-solid phase on a solid support. Calcein was spotted on a polystyrene surface using a capillary compound holder device as depicted in Fig. 4 with capillary tubes arranged at a centre to centre distance of 2 mm. The density of overlying cells, suspended in the semi-solid phase (RPMI 1640 medium, 10% FCS, 1% Pen-Strep, 0.34% agar) was 10E7 cells (MT4)/ml. Detection was carried out by fluorescence microscopy after a two hour incubation period.
- Fig. 14 is a schematic representation of an automated method for the rapid screening of compounds in accordance with the invention.
- An information carrier 30 in the form of a film or tape and with compounds to be screened applied as discrete spots or lines on its surface 31 is brought into contact with surface 32 of an information carrier 33, which is also a film or tape, bearing targets of interest embedded in a semi-solid matrix.
- the respective carriers 30, 33 are then wound with their surfaces 31 and 32 in contact and incubated in a temperature, humidity and carbon dioxide controlled environment, such that the compounds are released to the surface 32 of the carrier 33.
- the carriers are then unwound and the carrier 33 is then passed to an analysis - and information reading unit indicated generally at 34.
- FIG. 15 there is indicated generally at 40, apparatus for feeding capillary tubes 41 from a supply thereof to a conveyor belt 42 with regularly spaced-apart transverse grooves 43.
- the capillary tubes 41 enter a channel 44 which can accommodate a single layer of capillary tubes 41 in response to the anti-clockwise movement of a belt 45 and are delivered one at a time to the grooves 43 as the conveyor belt 42 moves in a clockwise direction.
- the capillary tubes 41 travel along the channel 44 through the combined effects of gravity and the belt 45.
- FIG. 16a-c and Fig. 17 the steps involved in transferring the capillary tubes 41 to a microtitre plate 47 for filling are illustrated.
- Capillary tubes 41 are lifted from the belt 42 by a clamping device indicated generally at 48.
- the clamping device 48 comprises two elongate members 49 which clamp a plurality of tubes
- the clamping device 48 lifts and transports the tubes 41 in groups of 12 corresponding to the number of wells 50 in one row of the microtitre plate 47. During the transporting step, the clamping device 48 is rotated through 90° so that one end of the capillary tubes 41 is lowered into the wells 50 of the microtitre plate 47.
- the clamping device 48 and the capillary tubes 41 are free to move along a vertical axis to allow the tubes 41 to be lowered into the wells 50 of the microtitre plate 47.
- the capillary tubes 41 are held in the wells 50 for a period of time sufficient to allow liquid in the respective wells 50 to be drawn into the tubes 41 by capillary action. Once the given filling time has elapsed, the tubes 41 are withdrawn and the clamping device 48 is rotated through 90° to again assume a horizontal orientation.
- the capillary tubes 41 are transferred to a screw - or worm device 51 which is used to reduce the spacing between the capillary tubes 41 as shown in Fig. 18.
- the capillary tubes 41 are delivered to the screw device 51 at end 52.
- Thread 53 of the screw device 51 has a varying pitch, being larger at end 52 than at end 54.
- the capillary tubes 41 advance along its length in the direction of the arrow and due to the changing pitch also come closer together.
- tubes 41 are only separated by wall 55 of the thread 53.
- the capillary tubes 41 are discharged from the screw device 51 onto a tape 56 which has a layer of adhesive to which the tubes 41 are stuck with their sides abutting.
- the tape 56 advances at the same rate as the tubes 41 leave the screw device 51.
- the tape 56 is then progressively rolled up into a tightly packed spiral array as shown at 57.
- apparatus for releasing the liquid in the capillary tubes 41 defining the array 57 to the surface of a solid support 61 and which is movable relative thereto.
- the apparatus 60 comprises a housing 62 which is adapted to receive said array 57.
- the housing 62 is connected to an air pump 63 and by creating an area of positive pressure relative to the exterior of the housing 62 forces the liquid out of the tubes 41 onto the surface of the solid support 61, when required.
- Fig. 21 shows the array 57 of capillary tubes 41 disposed above the solid support 61 following application of droplets of liquid analytes from the tubes 41 and the pattern of discrete spots 64 disposed on said solid support 61.
- Fig. 22 is a plan view of the solid support 61 showing the spiral arrangement of the discrete spots 64 of the applied liquid analyte.
- FIG. 23 there is illustrated a device indicated generally at 70, for applying target cells in a semi-solid phase 71 to surface 72 of the solid support 61 following drying of the liquid analytes.
- Device 70 comprises an arm 73 and a printing head 74.
- the solid support 61 is free to rotate and the device 70 is free to move in the z plane and x or y planes, so that the printing head 74 is located by a combination of motion of the arm 73 and the solid support 61.
- the microorganism identified under I above was accompanied by:
- BCCMTM/LMBP curator BELGIAN COORDINATED COLLECTIONS OF MICROORGANISMS - BCCMTM/ LMBP-COLLECTION
- the said microorganism was: (mark the applicable box with a cross)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Clinical Laboratory Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01204142A EP1250955A1 (en) | 1998-09-08 | 1998-09-08 | Method for the rapid screening of analytes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1998/001399 WO2000014540A1 (en) | 1998-09-08 | 1998-09-08 | Method for the rapid screening of analytes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01204142A Division EP1250955A1 (en) | 1998-09-08 | 1998-09-08 | Method for the rapid screening of analytes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1112494A1 true EP1112494A1 (en) | 2001-07-04 |
Family
ID=11004751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98940489A Withdrawn EP1112494A1 (en) | 1998-09-08 | 1998-09-08 | Method for the rapid screening of analytes |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1112494A1 (ru) |
JP (1) | JP2003517575A (ru) |
KR (1) | KR100562872B1 (ru) |
CN (1) | CN1315001A (ru) |
AU (1) | AU771520B2 (ru) |
BR (1) | BR9816009A (ru) |
CA (1) | CA2342627A1 (ru) |
IL (1) | IL141810A (ru) |
MX (1) | MXPA01002431A (ru) |
NZ (1) | NZ510765A (ru) |
PL (1) | PL346565A1 (ru) |
RU (1) | RU2225985C2 (ru) |
TR (1) | TR200101255T2 (ru) |
TW (1) | TW429312B (ru) |
WO (1) | WO2000014540A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
DE10034570A1 (de) * | 2000-07-14 | 2002-01-31 | Max Delbrueck Centrum | Verfahren zur Herstellung von Mikroarray-Chips mit Nukleinsäuren, Proteinen oder anderen Testsubstanzen |
AU2002223529B2 (en) * | 2000-09-07 | 2006-08-24 | Tibotec Bvba | Automated system for filling capillaries |
US7524455B2 (en) * | 2003-11-24 | 2009-04-28 | General Electric Company | Methods for deposition of sensor regions onto optical storage media substrates and resulting devices |
JP2005172475A (ja) * | 2003-12-08 | 2005-06-30 | Mitsubishi Rayon Co Ltd | バイオアッセイプレート及びそれを用いたバイオアッセイ方法 |
DE102007056398A1 (de) * | 2007-11-23 | 2009-05-28 | Febit Holding Gmbh | Flexibles Extraktionsverfahren für die Herstellung sequenzspezifischer Molekülbibliotheken |
CN101339167B (zh) * | 2008-08-27 | 2011-12-14 | 中国药科大学 | 基于靶蛋白亲和选择的活性成分高通量筛选方法 |
RU2558229C2 (ru) * | 2013-04-19 | 2015-07-27 | Общество с ограниченной ответственностью "Ген Эксперт" | Набор и способ для приготовления многослойных агарозных блоков на поверхности мини-стекол для микроскопии |
CN110799654A (zh) | 2017-03-21 | 2020-02-14 | 穆韦尔斯有限公司 | 密封微孔测定法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011779A (en) * | 1988-01-21 | 1991-04-30 | Long Island Jewish Medical Center | Apparatus for rapid deposition of test samples on an absorbent support |
WO1995011450A1 (en) * | 1993-10-20 | 1995-04-27 | Medical Research Council | Improvements in or relating to electrophoresis |
WO1998029736A1 (en) * | 1996-12-31 | 1998-07-09 | Genometrix Incorporated | Multiplexed molecular analysis apparatus and method |
WO1999030154A2 (en) * | 1997-12-12 | 1999-06-17 | Abbott Laboratories | Continuous format high throughput screening |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE431257B (sv) * | 1977-11-03 | 1984-01-23 | Du Pont | Sett och anordning for immunanalys med magnetisk metall eller metalloxid som merksubstans |
US4276048A (en) * | 1979-06-14 | 1981-06-30 | Dynatech Ag | Miniature reaction container and a method and apparatus for introducing micro volumes of liquid to such a container |
US5856083A (en) * | 1994-05-06 | 1999-01-05 | Pharmacopeia, Inc. | Lawn assay for compounds that affect enzyme activity or bind to target molecules |
EP0918845A4 (en) * | 1996-07-08 | 2000-08-30 | Burstein Lab Inc | METHOD AND APPARATUS WITH CLIVABLE SIGNAL ELEMENT |
JP2001504219A (ja) * | 1996-11-11 | 2001-03-27 | ノバルティス アクチェンゲゼルシャフト | 植物の病気を診断するためのバイオセンサーの使用 |
-
1998
- 1998-09-08 KR KR1020017002960A patent/KR100562872B1/ko not_active IP Right Cessation
- 1998-09-08 TR TR2001/01255T patent/TR200101255T2/xx unknown
- 1998-09-08 CA CA002342627A patent/CA2342627A1/en not_active Abandoned
- 1998-09-08 CN CN98814290A patent/CN1315001A/zh active Pending
- 1998-09-08 RU RU2001109257/15A patent/RU2225985C2/ru not_active IP Right Cessation
- 1998-09-08 EP EP98940489A patent/EP1112494A1/en not_active Withdrawn
- 1998-09-08 IL IL14181098A patent/IL141810A/xx not_active IP Right Cessation
- 1998-09-08 JP JP2000569234A patent/JP2003517575A/ja not_active Withdrawn
- 1998-09-08 NZ NZ510765A patent/NZ510765A/en unknown
- 1998-09-08 MX MXPA01002431A patent/MXPA01002431A/es unknown
- 1998-09-08 BR BR9816009-5A patent/BR9816009A/pt not_active Application Discontinuation
- 1998-09-08 WO PCT/IB1998/001399 patent/WO2000014540A1/en not_active Application Discontinuation
- 1998-09-08 AU AU22512/00A patent/AU771520B2/en not_active Ceased
- 1998-09-08 PL PL98346565A patent/PL346565A1/xx not_active IP Right Cessation
-
2000
- 2000-02-21 TW TW089102946A patent/TW429312B/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011779A (en) * | 1988-01-21 | 1991-04-30 | Long Island Jewish Medical Center | Apparatus for rapid deposition of test samples on an absorbent support |
WO1995011450A1 (en) * | 1993-10-20 | 1995-04-27 | Medical Research Council | Improvements in or relating to electrophoresis |
WO1998029736A1 (en) * | 1996-12-31 | 1998-07-09 | Genometrix Incorporated | Multiplexed molecular analysis apparatus and method |
WO1999030154A2 (en) * | 1997-12-12 | 1999-06-17 | Abbott Laboratories | Continuous format high throughput screening |
Non-Patent Citations (1)
Title |
---|
See also references of WO0014540A1 * |
Also Published As
Publication number | Publication date |
---|---|
IL141810A0 (en) | 2002-03-10 |
CA2342627A1 (en) | 2000-03-16 |
WO2000014540A1 (en) | 2000-03-16 |
MXPA01002431A (es) | 2002-05-08 |
TW429312B (en) | 2001-04-11 |
KR20010106467A (ko) | 2001-11-29 |
BR9816009A (pt) | 2001-06-05 |
AU2251200A (en) | 2000-03-27 |
JP2003517575A (ja) | 2003-05-27 |
AU771520B2 (en) | 2004-03-25 |
RU2225985C2 (ru) | 2004-03-20 |
NZ510765A (en) | 2003-09-26 |
TR200101255T2 (tr) | 2001-10-22 |
PL346565A1 (en) | 2002-02-11 |
IL141810A (en) | 2005-08-31 |
CN1315001A (zh) | 2001-09-26 |
KR100562872B1 (ko) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4387588B2 (ja) | 高スループットスクリーニングアッセイ用仮想ウェル | |
JP4361271B2 (ja) | アッセイ、合成、および保存用の器具、ならびに、その作製、使用、および操作の方法 | |
US20150298089A1 (en) | Systems for Filling a Sample Array by Droplet Dragging | |
US6893877B2 (en) | Methods for screening substances in a microwell array | |
CA2427990C (en) | Improved cell carrier grids | |
AU771520B2 (en) | Method for the rapid screening of analytes | |
US20020081629A1 (en) | Apparatus for the simultaneous transfer of liquid analytes | |
EP1250955A1 (en) | Method for the rapid screening of analytes | |
Brenan et al. | Massively parallel microfluidics platform for storage and ultra-high-throughput screening | |
Kanigan et al. | Living chips for drug discovery | |
SU946517A1 (ru) | Способ приготовлени комплексов ДНК с белком дл электронно-микроскопического исследовани |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010409 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20040514 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TIBOTEC BVBA |
|
17Q | First examination report despatched |
Effective date: 20040514 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070815 |